TY - JOUR
T1 - Microenvironmental modulation in tandem with human stem cell transplantation enhances functional recovery after chronic complete spinal cord injury
AU - Hashimoto, Shogo
AU - Nagoshi, Narihito
AU - Shinozaki, Munehisa
AU - Nakanishi, Katsuyuki
AU - Suematsu, Yu
AU - Shibata, Takahiro
AU - Kawai, Momotaro
AU - Kitagawa, Takahiro
AU - Ago, Kentaro
AU - Kamata, Yasuhiro
AU - Yasutake, Kaori
AU - Koya, Ikuko
AU - Ando, Yoshinari
AU - Minoda, Aki
AU - Shindo, Tomoko
AU - Shibata, Shinsuke
AU - Matsumoto, Morio
AU - Nakamura, Masaya
AU - Okano, Hideyuki
N1 - Funding Information:
We appreciate the assistance and instruction provided by Drs. Y. Tanimoto, Y. Hoshino, R. Shibata, K. Kajikawa, L. Tao, T. Nishijima, Y. Saijo, T. Yoshida, K. Ito, T. Tanaka, all of whom are members of the Spinal Cord Research Team at the Department of Orthopedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan. We thank Prof. S. Yamanaka (Kyoto University, Kyoto, Japan) for the human iPSC clones, Dr. Y. Miyashita (The University of Tokyo, Tokyo, Japan) for providing the vector containing WGA, Gunze, Inc. (Kyoto, Japan) for providing PGp and some images, and Kringle Pharma, Inc. (Osaka, Japan) for providing the rhHGF. We also thank M. Akizawa, T. Kobayashi, and T. Harada for their assistance with the experiments and animal care. This work was supported by the following grants: Research Center Network for Realization of Regenerative Medicine by AMED Japan (grant Nos. JP22bk0104114 , JP21bm0204001 , JP20bm0204001 , JP19bm0204001 , JP20bk0104017 , and JP19bk0104017 to H.O. and M.N. and JP22bm0704046 to S.S. and T.S.), Keio University Grant-in-Aid for Encouragement of Young Medical Scientists (2020 and 2021) to S.H., Keio Medical Association Medical Research Grants (2021) to S.H.; a grant from the Keio Orthopaedic Hosoya and Umezawa Foundation (2020) to S.H., and a grant from the Keio-SPRING Program supported by JST to K.N.
Funding Information:
We appreciate the assistance and instruction provided by Drs. Y. Tanimoto, Y. Hoshino, R. Shibata, K. Kajikawa, L. Tao, T. Nishijima, Y. Saijo, T. Yoshida, K. Ito, T. Tanaka, all of whom are members of the Spinal Cord Research Team at the Department of Orthopedic Surgery and Physiology, Keio University School of Medicine, Tokyo, Japan. We thank Prof. S. Yamanaka (Kyoto University, Kyoto, Japan) for the human iPSC clones, Dr. Y. Miyashita (The University of Tokyo, Tokyo, Japan) for providing the vector containing WGA, Gunze, Inc. (Kyoto, Japan) for providing PGp and some images, and Kringle Pharma, Inc. (Osaka, Japan) for providing the rhHGF. We also thank M. Akizawa, T. Kobayashi, and T. Harada for their assistance with the experiments and animal care. This work was supported by the following grants: Research Center Network for Realization of Regenerative Medicine by AMED Japan (grant Nos. JP22bk0104114, JP21bm0204001, JP20bm0204001, JP19bm0204001, JP20bk0104017, and JP19bk0104017 to H.O. and M.N. and JP22bm0704046 to S.S. and T.S.), Keio University Grant-in-Aid for Encouragement of Young Medical Scientists (2020 and 2021) to S.H. Keio Medical Association Medical Research Grants (2021) to S.H.; a grant from the Keio Orthopaedic Hosoya and Umezawa Foundation (2020) to S.H. and a grant from the Keio-SPRING Program supported by JST to K.N.
Publisher Copyright:
© 2023 The Authors
PY - 2023/4
Y1 - 2023/4
N2 - While rapid advancements in regenerative medicine strategies for spinal cord injury (SCI) have been made, most research in this field has focused on the early stages of incomplete injury. However, the majority of patients experience chronic severe injury; therefore, treatments for these situations are fundamentally important. Here, we hypothesized that environmental modulation via a clinically relevant hepatocyte growth factor (HGF)-releasing scaffold and human iPS cell-derived neural stem/progenitor cells (hNS/PCs) transplantation contributes to functional recovery after chronic complete transection SCI. Effective release of HGF from a collagen scaffold induced progressive axonal elongation and increased grafted cell viability by activating microglia/macrophages and meningeal cells, inhibiting inflammation, reducing scar formation, and enhancing vascularization. Furthermore, hNS/PCs transplantation enhanced endogenous neuronal regrowth, the extension of graft axons, and the formation of circuits around the lesion and lumbar enlargement between host and graft neurons, resulting in the restoration of locomotor and urinary function. This study presents an effective therapeutic strategy for severe chronic SCI and provides evidence for the feasibility of regenerative medicine strategies using clinically relevant materials.
AB - While rapid advancements in regenerative medicine strategies for spinal cord injury (SCI) have been made, most research in this field has focused on the early stages of incomplete injury. However, the majority of patients experience chronic severe injury; therefore, treatments for these situations are fundamentally important. Here, we hypothesized that environmental modulation via a clinically relevant hepatocyte growth factor (HGF)-releasing scaffold and human iPS cell-derived neural stem/progenitor cells (hNS/PCs) transplantation contributes to functional recovery after chronic complete transection SCI. Effective release of HGF from a collagen scaffold induced progressive axonal elongation and increased grafted cell viability by activating microglia/macrophages and meningeal cells, inhibiting inflammation, reducing scar formation, and enhancing vascularization. Furthermore, hNS/PCs transplantation enhanced endogenous neuronal regrowth, the extension of graft axons, and the formation of circuits around the lesion and lumbar enlargement between host and graft neurons, resulting in the restoration of locomotor and urinary function. This study presents an effective therapeutic strategy for severe chronic SCI and provides evidence for the feasibility of regenerative medicine strategies using clinically relevant materials.
KW - Cell transplantation therapy
KW - Chronic phase
KW - Hepatocyte growth factor
KW - iPS cell
KW - Scaffold
KW - Spinal cord transection injury
UR - http://www.scopus.com/inward/record.url?scp=85149779414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149779414&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2023.122002
DO - 10.1016/j.biomaterials.2023.122002
M3 - Article
C2 - 36736008
AN - SCOPUS:85149779414
SN - 0142-9612
VL - 295
JO - Biomaterials
JF - Biomaterials
M1 - 122002
ER -